Interest in Vitamin K2 for children’s growth continues to grow. A newly published study in Nutrients (Nguyen et al., 2026) is the third to examine growth outcomes in children with finished products featuring MenaQ7®, the Vitamin K2 (MK-7).
Conducted in Vietnam between March 2022 and June 2025, this retrospective, longitudinal, observational study followed 1,150 healthy children aged 6 to 14 years. 537 children received MenaQ7® at 360 µg/day, taken continuously from the start of the study, for a follow-up period ranging from a few months to 30 months. 613 children served as controls.
A Growing Body of Evidence
Children taking a multinutrient supplement containing MenaQ7® vitamin K2 MK-7 continuously gained more height over time. The longer the follow-up, the clearer the association became.
Among children followed for more than 12 months, those in the vitamin K2 MK-7 group gained on average about 1.85 cm more than the controls: +9.88 cm versus +8.03 cm (p<0.001).
This study builds on previous research featuring MenaQ7®:
- A study of 945 children aged 1 to 14 years found that continuous MenaQ7® supplementation (180-360 µg/day) was associated with improved height growth, with the strongest association in children aged 1 to 5 years.
- A nationwide study of 43,505 children aged 6 to 17 years found that children taking Vitamin K2 daily, including finished products with MenaQ7®, had 18% lower odds of impaired growth compared to those who did not.
Different designs, different populations, different age groups, and one common thread: MenaQ7® featured in every study. For brands developing products for children, this growing body of research is a strong signal of the value of regular, long-term use.